Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Nymox Pharmaceutical Corp?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Nymox Pharmaceutical Corp market cap is $17.34M.
What is the 52-week high for Nymox Pharmaceutical Corp?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Nymox Pharmaceutical Corp 52 week high is $1.28 as of July 02, 2024.
What is the 52-week low for Nymox Pharmaceutical Corp?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Nymox Pharmaceutical Corp 52 week low is $0.0501 as of July 02, 2024.
What is Nymox Pharmaceutical Corp stock price today?
Nymox Pharmaceutical Corp stock price today is $0.20.
What was Nymox Pharmaceutical Corp stock price yesterday?
Nymox Pharmaceutical Corp stock price yesterday was $0.19.
What is the PE ratio of Nymox Pharmaceutical Corp?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Nymox Pharmaceutical Corp’s P/E ratio is -3.55.
What is the Price-to-Book ratio of Nymox Pharmaceutical Corp?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Nymox Pharmaceutical Corp P/B ratio is -9.3183.
What is Nymox Pharmaceutical Corp's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Nymox Pharmaceutical Corp's EBITDA is -26.64.
What is the 50-day moving average of Nymox Pharmaceutical Corp?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Nymox Pharmaceutical Corp 50-day moving average is $0.234.